Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile.

Literature DB >> 21709084

Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile.

Farah Babakhani¹, Abraham Gomez, Nikki Robert, Pamela Sears.

Abstract

Fidaxomicin (FDX), a narrow-spectrum antibiotic recently shown to be superior to vancomycin in providing sustained clinical response to Clostridium difficile infection, was investigated along with its major metabolite, OP-1118, with regard to their postantibiotic effects (PAE). FDX was found to have a prolonged PAE (10 h versus ATCC strains and 5.5 h versus a clinical isolate), and OP-1118's PAE was longer than that of the standard comparator, vancomycin (3 versus 0 to 1.5 h, respectively).

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2011 PMID： 21709084 PMCID： PMC3165303 DOI： 10.1128/AAC.00104-11

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

14 in total

Review 1. Alternative treatments for Clostridium difficile disease: what really works?

Authors: Lynne V McFarland
Journal: J Med Microbiol Date: 2005-02 Impact factor: 2.472

2. Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species.

Authors: Kim L Credito; Peter C Appelbaum
Journal: Antimicrob Agents Chemother Date: 2004-11 Impact factor: 5.191

3. Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses.

Authors: Y K Shue; P S Sears; S Shangle; R B Walsh; C Lee; S L Gorbach; F Okumu; R A Preston
Journal: Antimicrob Agents Chemother Date: 2008-02-11 Impact factor: 5.191

4. In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile.

Authors: James A Karlowsky; Nancy M Laing; George G Zhanel
Journal: Antimicrob Agents Chemother Date: 2008-08-25 Impact factor: 5.191

5. OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection.

Authors: Thomas J Louie; Judy Emery; Walter Krulicki; Brendan Byrne; Manuel Mah
Journal: Antimicrob Agents Chemother Date: 2008-10-27 Impact factor: 5.191

6. Pharmacodynamic studies of vancomycin, metronidazole and fusidic acid against Clostridium difficile.

Authors: Inga Odenholt; Mats Walder; Marlene Wullt
Journal: Chemotherapy Date: 2007-06-25 Impact factor: 2.544

7. Postantibiotic sub-MIC effects of vancomycin, roxithromycin, sparfloxacin, and amikacin.

Authors: I Odenholt-Tornqvist; E Löwdin; O Cars
Journal: Antimicrob Agents Chemother Date: 1992-09 Impact factor: 5.191

8. In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004.

Authors: David W Hecht; Minerva A Galang; Susan P Sambol; James R Osmolski; Stuart Johnson; Dale N Gerding
Journal: Antimicrob Agents Chemother Date: 2007-05-21 Impact factor: 5.191

9. In vitro activity of OPT-80 against Clostridium difficile.

Authors: Grit Ackermann; Birgit Löffler; Daniela Adler; Arne C Rodloff
Journal: Antimicrob Agents Chemother Date: 2004-06 Impact factor: 5.191

Review 10. Clostridium difficile infection: new developments in epidemiology and pathogenesis.

Authors: Maja Rupnik; Mark H Wilcox; Dale N Gerding
Journal: Nat Rev Microbiol Date: 2009-07 Impact factor: 60.633

21 in total

1. Fidaxomicin: in Clostridium difficile infection.

Authors: Sean T Duggan
Journal: Drugs Date: 2011-12-24 Impact factor: 9.546

2. Fidaxomicin and OP-1118 Inhibit Clostridium difficile Toxin A- and B-Mediated Inflammatory Responses via Inhibition of NF-κB Activity.

Authors: Hon Wai Koon; Jiani Wang; Caroline C Mussatto; Christina Ortiz; Elaine C Lee; Diana Hoang-Ngoc Tran; Xinhua Chen; Ciaran P Kelly; Charalabos Pothoulakis
Journal: Antimicrob Agents Chemother Date: 2017-12-21 Impact factor: 5.191

3. Fidaxomicin therapy in critically ill patients with Clostridium difficile infection.

Authors: Samuel Penziner; Yanina Dubrovskaya; Robert Press; Amar Safdar
Journal: Antimicrob Agents Chemother Date: 2014-12-22 Impact factor: 5.191

4. The efficacy of fidaxomicin in the treatment of Clostridium difficile infection in a real-world clinical setting: a Spanish multi-centre retrospective cohort.

Authors: C Fehér; E Múñez Rubio; P Merino Amador; A Delgado-Iribarren Garcia-Campero; M Salavert; E Merino; E Maseda Garrido; V Díaz-Brito; M J Álvarez; J Mensa
Journal: Eur J Clin Microbiol Infect Dis Date: 2016-10-08 Impact factor: 3.267

5. Clinical and Economic Outcomes After Implementation of a Fidaxomicin Treatment Optimization and Access Pathway at a US Hospital System.

Authors: Lauren F McDaniel; Melissa N White; Engels N Obi; Rose M Kohinke; Ellen Rachel S Lockhart; Damian J Chipriano; Yiyun Chen; Nathan A Everson
Journal: Infect Dis Ther Date: 2022-07-19

Review 6. Fidaxomicin in Clostridium difficile infection: latest evidence and clinical guidance.

Authors: Kathleen Mullane
Journal: Ther Adv Chronic Dis Date: 2014-03 Impact factor: 5.091

7. Comparative microbiological studies of transcription inhibitors fidaxomicin and the rifamycins in Clostridium difficile.

Authors: Farah Babakhani; Jaime Seddon; Pamela Sears
Journal: Antimicrob Agents Chemother Date: 2014-02-18 Impact factor: 5.191